Tyra Biosciences, Inc. 8-K

What Happened Tyra Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on May 28, 2026 and filed an 8-K on June 2, 2026 reporting the voting results. Shareholders elected three Class II directors to three-year terms expiring at the 2029 Annual Meeting and ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Director elections (Class II, term through 2029 Annual Meeting):
  • Habib J. Dable — For: 44,242,803; Withheld: 476,602; Broker non-votes: 8,377,977
  • Susan Moran, M.D., M.S.C.E. — For: 44,529,688; Withheld: 189,717; Broker non-votes: 8,377,977
  • Robert More — For: 41,013,686; Withheld: 3,705,719; Broker non-votes: 8,377,977
• Auditor ratification:
  • Ernst & Young LLP ratified for fiscal 2026 — For: 53,092,820; Against: 1,316; Abstain: 3,246; Broker non-votes: none reported

Why It Matters Board elections and auditor ratification are governance items that confirm shareholder support for management’s slate and audit continuity. The vote totals show strong support for Habib Dable and Susan Moran, while Robert More received a notably higher number of withheld votes. The consistent broker non-votes indicate a portion of shares held by brokers that were not voted on the director elections, which can affect the final tallies but do not change the fact that all three nominees were elected and the auditor was ratified.